See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is a chemotherapy drug used to treat certain types of cancer, including small cell lung cancer and ovarian cancer [2]. It works by blocking the activity of an enzyme that is necessary for cancer cells to divide and grow [2].

According to DrugPatentWatch, lurbinectedin is typically used in combination with other chemotherapy drugs [1]. The drug has been studied in combination with doxorubicin, a chemotherapy drug used to treat various types of cancer [1]. A phase 1b/2 clinical trial evaluated the safety and efficacy of the combination of lurbinectedin and doxorubicin in patients with relapsed small cell lung cancer and showed promising results [3].

In addition to doxorubicin, lurbinectedin has also been studied in combination with cisplatin, another chemotherapy drug used to treat various types of cancer [1]. A phase 1b/2 clinical trial evaluated the safety and efficacy of the combination of lurbinectedin and cisplatin in patients with relapsed small cell lung cancer and showed promising results [3].

It is important to note that the use of lurbinectedin in combination with other chemotherapy drugs may increase the risk of side effects [2]. Common side effects of lurbinectedin include fatigue, nausea, vomiting, decreased appetite, and constipation [2]. Patients should discuss the potential benefits and risks of using lurbinectedin in combination with other chemotherapy drugs with their healthcare provider [2].

Sources:
[1] DrugPatentWatch. Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] MedlinePlus. Lurbinectedin. Retrieved from https://medlineplus.gov/druginfo/meds/a620049.html
[3] Trigo, J., Subbiah, V., Besse, B., Moreno, V., Lopez, R., Sala, M.A., et al. (2020). Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. The Lancet Oncology, 21(5), 645-654. doi: 10.1016/S1470-2045(20)30068-1